Anavex Life Sciences Corp.
AVXL
$9.42
-$0.03-0.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.44% | -7.48% | -17.66% | -14.36% | -13.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.91% | -4.46% | -11.43% | -11.77% | -4.33% |
| Operating Income | -7.91% | 4.46% | 11.43% | 11.77% | 4.33% |
| Income Before Tax | -8.00% | 9.28% | 19.11% | 22.70% | 13.33% |
| Income Tax Expenses | -418.52% | -1,328.57% | -109.26% | -75.02% | -91.23% |
| Earnings from Continuing Operations | -7.73% | 9.48% | 19.60% | 23.03% | 13.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.73% | 9.48% | 19.60% | 23.03% | 13.81% |
| EBIT | -7.91% | 4.46% | 11.43% | 11.77% | 4.33% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.08% | 13.85% | 23.81% | 26.81% | 17.27% |
| Normalized Basic EPS | -5.59% | 11.95% | 21.86% | 25.21% | 18.58% |
| EPS Diluted | -3.08% | 13.85% | 23.81% | 26.81% | 17.66% |
| Normalized Diluted EPS | -5.59% | 11.95% | 21.86% | 25.21% | 18.58% |
| Average Basic Shares Outstanding | 4.14% | 4.62% | 5.23% | 5.21% | 4.57% |
| Average Diluted Shares Outstanding | 4.14% | 4.62% | 5.23% | 5.21% | 4.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |